ACAD
Price
$21.01
Change
+$0.13 (+0.62%)
Updated
Jul 8, 04:59 PM (EDT)
Capitalization
3.52B
21 days until earnings call
RGNX
Price
$8.74
Change
+$0.31 (+3.68%)
Updated
Jul 8 closing price
Capitalization
440.4M
21 days until earnings call
Interact to see
Advertisement

ACAD vs RGNX

Header iconACAD vs RGNX Comparison
Open Charts ACAD vs RGNXBanner chart's image
ACADIA Pharmaceuticals
Price$21.01
Change+$0.13 (+0.62%)
Volume$11.33K
Capitalization3.52B
REGENXBIO
Price$8.74
Change+$0.31 (+3.68%)
Volume$620.77K
Capitalization440.4M
ACAD vs RGNX Comparison Chart in %
Loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACAD vs. RGNX commentary
Jul 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a Buy and RGNX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 09, 2025
Stock price -- (ACAD: $21.02 vs. RGNX: $8.74)
Brand notoriety: ACAD and RGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACAD: 85% vs. RGNX: 55%
Market capitalization -- ACAD: $3.52B vs. RGNX: $440.4M
ACAD [@Biotechnology] is valued at $3.52B. RGNX’s [@Biotechnology] market capitalization is $440.4M. The market cap for tickers in the [@Biotechnology] industry ranges from $309.49B to $0. The average market capitalization across the [@Biotechnology] industry is $2.39B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACAD’s FA Score shows that 1 FA rating(s) are green whileRGNX’s FA Score has 1 green FA rating(s).

  • ACAD’s FA Score: 1 green, 4 red.
  • RGNX’s FA Score: 1 green, 4 red.
According to our system of comparison, ACAD is a better buy in the long-term than RGNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACAD’s TA Score shows that 2 TA indicator(s) are bullish while RGNX’s TA Score has 4 bullish TA indicator(s).

  • ACAD’s TA Score: 2 bullish, 5 bearish.
  • RGNX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, RGNX is a better buy in the short-term than ACAD.

Price Growth

ACAD (@Biotechnology) experienced а -1.59% price change this week, while RGNX (@Biotechnology) price change was +6.20% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.39%. For the same industry, the average monthly price growth was +14.41%, and the average quarterly price growth was +12.94%.

Reported Earning Dates

ACAD is expected to report earnings on Nov 11, 2025.

RGNX is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+9.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACAD($3.52B) has a higher market cap than RGNX($440M). ACAD YTD gains are higher at: 14.550 vs. RGNX (13.066). ACAD has higher annual earnings (EBITDA): 102M vs. RGNX (-122.44M). ACAD has more cash in the bank: 682M vs. RGNX (268M). ACAD has less debt than RGNX: ACAD (56M) vs RGNX (79.8M). ACAD has higher revenues than RGNX: ACAD (996M) vs RGNX (157M).
ACADRGNXACAD / RGNX
Capitalization3.52B440M800%
EBITDA102M-122.44M-83%
Gain YTD14.55013.066111%
P/E Ratio15.34N/A-
Revenue996M157M634%
Total Cash682M268M254%
Total Debt56M79.8M70%
FUNDAMENTALS RATINGS
ACAD vs RGNX: Fundamental Ratings
ACAD
RGNX
OUTLOOK RATING
1..100
5256
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
73
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
2696
PRICE GROWTH RATING
1..100
4651
P/E GROWTH RATING
1..100
10022
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACAD's Valuation (61) in the Biotechnology industry is in the same range as RGNX (73). This means that ACAD’s stock grew similarly to RGNX’s over the last 12 months.

ACAD's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RGNX (100). This means that ACAD’s stock grew similarly to RGNX’s over the last 12 months.

ACAD's SMR Rating (26) in the Biotechnology industry is significantly better than the same rating for RGNX (96). This means that ACAD’s stock grew significantly faster than RGNX’s over the last 12 months.

ACAD's Price Growth Rating (46) in the Biotechnology industry is in the same range as RGNX (51). This means that ACAD’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's P/E Growth Rating (22) in the Biotechnology industry is significantly better than the same rating for ACAD (100). This means that RGNX’s stock grew significantly faster than ACAD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACADRGNX
RSI
ODDS (%)
Bearish Trend 2 days ago
76%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 1 day ago
75%
Momentum
ODDS (%)
Bearish Trend 2 days ago
62%
Bullish Trend 1 day ago
74%
MACD
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
70%
Bullish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 21 days ago
73%
Bullish Trend 6 days ago
76%
Declines
ODDS (%)
Bearish Trend 2 days ago
71%
Bearish Trend 9 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
72%
N/A
Aroon
ODDS (%)
N/A
Bearish Trend 1 day ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HAVGX25.41N/A
N/A
Haverford Quality Growth Stock
FMIFX23.33N/A
N/A
FMI International II Ccy UnH Ins
IVOCX19.30N/A
N/A
Macquarie Mid Cap Income Opps C
KGGAX15.11N/A
N/A
Kopernik Global All-Cap A
JGRJX39.11-0.10
-0.26%
JPMorgan Growth Advantage R2

ACAD and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACAD has been loosely correlated with AURA. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ACAD jumps, then AURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACAD
1D Price
Change %
ACAD100%
+0.67%
AURA - ACAD
44%
Loosely correlated
+1.46%
CRSP - ACAD
43%
Loosely correlated
+7.09%
STTK - ACAD
39%
Loosely correlated
+4.84%
TECH - ACAD
39%
Loosely correlated
+2.22%
PGEN - ACAD
39%
Loosely correlated
+6.92%
More